A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema.
about
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsClassification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working GroupPharmacogenetics and Predictive Testing of Drug Hypersensitivity ReactionsLoss of function mutation in the palmitoyl-transferase HHAT leads to syndromic 46,XY disorder of sex development by impeding Hedgehog protein palmitoylation and signalingPhenotype standardization of angioedema in the head and neck region caused by agents acting on the angiotensin system.Icatibant , the bradykinin B2 receptor antagonist with target to the interconnected kinin systems.Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis.An update on the pharmacogenetics of treating hypertension.Genetics of Hereditary Angioedema Revisited.HAE Pathophysiology and Underlying Mechanisms.Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors.Hereditary angioedema with F12 mutation: factors modifying the clinical phenotype.Crystal structure of a novel prolidase from Deinococcus radiodurans identifies new subfamily of bacterial prolidases.XPNPEP2 is overexpressed in cervical cancer and promotes cervical cancer metastasis.Structure of the human aminopeptidase XPNPEP3 and comparison of its in vitro activity with Icp55 orthologs: Insights into diverse cellular processes.Icatibant in angiotensin-converting enzyme (ACE) inhibitor-associated angioedema.
P2860
Q27004000-B45995E8-C8BD-4ED9-91C8-F3364BCA1052Q27009012-585C2FBD-86B3-4AEB-A9BF-8B2E4D09A1F8Q28066096-C9EE98CF-8BE3-4843-ADC3-C37CD49F7754Q33553088-0032B2ED-4920-45C5-AE88-AF6A3AF78592Q34232188-33E288F2-DC66-4BF3-AB41-919033144E51Q38042696-E9FA0498-E4AB-4C01-B4DB-AD355C7F9393Q38080145-D87BF7EA-941A-4F23-8026-6F4A11576613Q38263731-0D3B1893-4894-4ED9-B53B-F3F24FA5FBE7Q38818135-671BFBF9-A72C-4332-8C81-AF8F5E93BC31Q38837708-38D31660-9BC4-4D3A-9C28-B7AF9B017F78Q40404536-1B04EF63-8317-472F-B420-71D8639298BCQ44495008-A3FF8DD4-E7DF-4E91-9C06-EB8FED8E1343Q46304080-0E6D46F2-5EB8-4FC5-8DAA-50BBA937EADAQ48625360-E0BFC078-BF0F-44CE-86F9-689B4D917C41Q51017615-34F2A91F-F13F-4CF2-A1A4-AD7905227AE2Q51633948-C86A91E7-2887-475E-83A3-198903C0EFE5
P2860
A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor-induced angioedema.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@en
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@en-gb
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@nl
type
label
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@en
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@en-gb
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@nl
prefLabel
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@en
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@en-gb
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@nl
P2093
P2860
P50
P356
P1433
P1476
A functional XPNPEP2 promoter ...... inhibitor-induced angioedema.
@en
P2093
Albert Adam
Amy L Cilia La Corte
Angela M Carter
Peter J Grant
Qing Ling Duan
P2860
P304
P356
10.1002/HUMU.21579
P577
2011-09-12T00:00:00Z